Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement

Dispenzieri, Angela; Rajkumar, S. Vincent; Gertz, Morie A.; Fonseca, Rafael; Lacy, Martha Q.; Bergsagel, P. Leif; Kyle, Robert A.; Greipp, Philip R.; Witzig, Thomas E.; Reeder, Craig B.; Lust, John A.; Russell, Stephen J.; Hayman, Suzanne R.; Roy, Vivek; Kumar, Shaji; Zeldenrust, Steven R.; Dalton, Robert J.; Stewart, A. Keith
March 2007
Mayo Clinic Proceedings;Mar2007, Vol. 82 Issue 3, p323
Academic Journal
Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.


Related Articles

  • Microenvironment: Dependency. Hutchinson, Ezzie // Nature Reviews Cancer;Sep2007, Vol. 7 Issue 9, p642 

    The article provides information on a medical research regarding the effect of extrinsic hedgehog (Hh) signaling from the stroma on the survival of B-cell lymphomas. Based on the results, B-cell malignancies are dependent on Hh signaling from the stroma for survival. Meanwhile, the researchers...

  • Millennium's Velcade gets full FDA approval.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p12 

    Reports on the commendation of Millennium Pharmaceuticals by the International Myeloma Foundation after receiving the United States Food and Drug Administration approval for Velcade in second-line multiple myeloma. Treatment of multiple myeloma patients who have received at least one prior...

  • A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Berenson, J R; Yellin, O; Kazamel, T; Hilger, J D; Chen, C-S; Cartmell, A; Woliver, T; Flam, M; Bravin, E; Nassir, Y; Vescio, R; Swift, R A // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1675 

    Our previous studies have shown that lowering the dose of pegylated liposomal doxorubicin (PLD) and bortezomib in combination with intravenous dexamethasone on a longer 4-week cycle maintained efficacy and improved tolerability in both previously untreated and relapsed/refractory (R/R) multiple...

  • Cure of multiple myeloma – more hype, less reality. Hari, P.; Pasquini, M. C.; Vesole, D. H. // Bone Marrow Transplantation;Jan2006, Vol. 37 Issue 1, p1 

    Randomized studies have firmly established the role of autologous transplant as initial therapy in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous SCT in North America. The conceptual basis for high-dose therapy is the goal of complete remission (CR)...

  • The molecular characterization and clinical management of multiple myeloma in the post-genome era. Zhou, Y.; Barlogie, B.; Shaughnessy, J. D.; Shaughnessy, J D Jr // Leukemia (08876924);Nov2009, Vol. 23 Issue 11, p1941 

    Cancer-causing mutations disrupt coordinated, precise programs of gene expression that govern cell growth and differentiation. Microarray-based gene-expression profiling (GEP) is a powerful tool to globally analyze these changes to study cancer biology and clinical behavior. Despite overwhelming...

  • Maintenance lenalidomide prolonged PFS in transplant-ineligible multiple myeloma.  // Hem/Onc Today;6/10/2012, Vol. 13 Issue 11, p22 

    The article reports on a study which found that multiple myeloma patients who are ineligible for stem cell transplants, have a longer progression-free survival rate when placed on maintenance therapy with lenalidomide.

  • Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Stessman, H A F; Mansoor, A; Zhan, F; Janz, S; Linden, M A; Baughn, L B; Van Ness, B // Leukemia (08876924);Oct2013, Vol. 27 Issue 10, p2075 

    A letter to the editor is presented in response to the article related to aspects of mouse model of myeloma and treatment of multiple myeloma patients in the May 31, 2013 issue.

  • Designing Risk-Adapted Therapy for Multiple Myeloma: The Mayo Perspective. Lonial, Sagar // Mayo Clinic Proceedings;Mar2007, Vol. 82 Issue 3, p279 

    The author reflects on the study investigating the treatments for patients with myeloma. He tries to point that despite the reseachers' recommended therapies that were believed to treat the disease, the eligibility of patients for high-dose therapy and autologous transplatation remains a...

  • Millennium: Velcade set for cancer consolidation.  // PharmaWatch: Cancer;Jan2006, Vol. 5 Issue 1, p14 

    The article reports that Millennium Pharmaceuticals Inc. has presented positive phase III survival data for Velcade in multiple myeloma. This data may further increase sales of Velcade. The trial enrolled 669 patients with multiple myeloma who had already received one to three prior therapies....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics